WO2022171153A1 - 消毒剂 - Google Patents
消毒剂 Download PDFInfo
- Publication number
- WO2022171153A1 WO2022171153A1 PCT/CN2022/075750 CN2022075750W WO2022171153A1 WO 2022171153 A1 WO2022171153 A1 WO 2022171153A1 CN 2022075750 W CN2022075750 W CN 2022075750W WO 2022171153 A1 WO2022171153 A1 WO 2022171153A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- disinfectant
- edta
- disinfectant according
- agent
- reducing agent
- Prior art date
Links
- 239000000645 desinfectant Substances 0.000 title claims abstract description 67
- 239000003638 chemical reducing agent Substances 0.000 claims abstract description 31
- 239000013543 active substance Substances 0.000 claims abstract description 30
- 239000000872 buffer Substances 0.000 claims abstract description 22
- 239000002738 chelating agent Substances 0.000 claims abstract description 11
- 230000000249 desinfective effect Effects 0.000 claims abstract description 11
- 241000711573 Coronaviridae Species 0.000 claims abstract description 10
- 239000012752 auxiliary agent Substances 0.000 claims abstract description 10
- 125000003396 thiol group Chemical group [H]S* 0.000 claims abstract description 9
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 26
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 23
- XIWFQDBQMCDYJT-UHFFFAOYSA-M benzyl-dimethyl-tridecylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 XIWFQDBQMCDYJT-UHFFFAOYSA-M 0.000 claims description 23
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims description 19
- 239000011734 sodium Substances 0.000 claims description 17
- 239000000126 substance Substances 0.000 claims description 16
- 235000010265 sodium sulphite Nutrition 0.000 claims description 13
- 239000007983 Tris buffer Substances 0.000 claims description 12
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 claims description 11
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 11
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 11
- 239000002671 adjuvant Substances 0.000 claims description 9
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 8
- 241000894006 Bacteria Species 0.000 claims description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 claims description 6
- 150000003242 quaternary ammonium salts Chemical group 0.000 claims description 6
- 239000003093 cationic surfactant Substances 0.000 claims description 5
- 241000588724 Escherichia coli Species 0.000 claims description 4
- 235000013878 L-cysteine Nutrition 0.000 claims description 4
- 239000004201 L-cysteine Substances 0.000 claims description 4
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims description 4
- 241000191967 Staphylococcus aureus Species 0.000 claims description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 4
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 claims description 4
- 229960003330 pentetic acid Drugs 0.000 claims description 4
- HLWRUJAIJJEZDL-UHFFFAOYSA-M sodium;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetate Chemical compound [Na+].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC([O-])=O HLWRUJAIJJEZDL-UHFFFAOYSA-M 0.000 claims description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 3
- 108010024636 Glutathione Proteins 0.000 claims description 3
- 229930003268 Vitamin C Natural products 0.000 claims description 3
- 229930003427 Vitamin E Natural products 0.000 claims description 3
- 229960002233 benzalkonium bromide Drugs 0.000 claims description 3
- 229960001950 benzethonium chloride Drugs 0.000 claims description 3
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 claims description 3
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 claims description 3
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims description 3
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 235000019154 vitamin C Nutrition 0.000 claims description 3
- 239000011718 vitamin C Substances 0.000 claims description 3
- 235000019165 vitamin E Nutrition 0.000 claims description 3
- 229940046009 vitamin E Drugs 0.000 claims description 3
- 239000011709 vitamin E Substances 0.000 claims description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 3
- VYTBPJNGNGMRFH-UHFFFAOYSA-N acetic acid;azane Chemical compound N.N.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O VYTBPJNGNGMRFH-UHFFFAOYSA-N 0.000 claims description 2
- DBLXOVFQHHSKRC-UHFFFAOYSA-N ethanesulfonic acid;2-piperazin-1-ylethanol Chemical compound CCS(O)(=O)=O.OCCN1CCNCC1 DBLXOVFQHHSKRC-UHFFFAOYSA-N 0.000 claims description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 claims description 2
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 claims 2
- AEELXMHQIJJMKP-QWWZWVQMSA-N (2r,3r)-3-sulfanylbutane-1,2,4-triol Chemical compound OC[C@@H](O)[C@H](S)CO AEELXMHQIJJMKP-QWWZWVQMSA-N 0.000 claims 1
- LZDKZFUFMNSQCJ-UHFFFAOYSA-N 1,2-diethoxyethane Chemical compound CCOCCOCC LZDKZFUFMNSQCJ-UHFFFAOYSA-N 0.000 claims 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000006172 buffering agent Substances 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 229960003180 glutathione Drugs 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 238000004659 sterilization and disinfection Methods 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 8
- 230000001954 sterilising effect Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 6
- 208000025721 COVID-19 Diseases 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- -1 Dettol Chemical class 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- YVOOPGWEIRIUOX-BXRBKJIMSA-N (2r)-2-azanyl-3-sulfanyl-propanoic acid Chemical compound SC[C@H](N)C(O)=O.SC[C@H](N)C(O)=O YVOOPGWEIRIUOX-BXRBKJIMSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 241001678559 COVID-19 virus Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000009972 noncorrosive effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OSDLLIBGSJNGJE-UHFFFAOYSA-N 4-chloro-3,5-dimethylphenol Chemical compound CC1=CC(O)=CC(C)=C1Cl OSDLLIBGSJNGJE-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- RUPBZQFQVRMKDG-UHFFFAOYSA-M Didecyldimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC RUPBZQFQVRMKDG-UHFFFAOYSA-M 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000711467 Human coronavirus 229E Species 0.000 description 1
- 241001109669 Human coronavirus HKU1 Species 0.000 description 1
- 241000482741 Human coronavirus NL63 Species 0.000 description 1
- 241001428935 Human coronavirus OC43 Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 1
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 1
- 241001292005 Nidovirales Species 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 229960004670 didecyldimethylammonium chloride Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- SVYHKSYGLHIYEJ-UHFFFAOYSA-N n-chlorohexadecan-1-amine Chemical compound CCCCCCCCCCCCCCCCNCl SVYHKSYGLHIYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N33/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds
- A01N33/02—Amines; Quaternary ammonium compounds
- A01N33/12—Quaternary ammonium compounds
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
- A01P1/00—Disinfectants; Antimicrobial compounds or mixtures thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
- A01P3/00—Fungicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to the field of disinfectants.
- Novel coronavirus pneumonia (referred to as “new coronary pneumonia” or “Covid-19”) is an acute infectious pneumonia for which there is currently no specific medicine. At present, the virus has spread widely around the world, infecting tens of millions of people.
- Phenols such as Dettol
- Hypochlorous acid such as 84 disinfectant, although it has a good bactericidal effect, it is very irritating and corrosive, and is often used for liquid disinfection, such as swimming pools, tap water, etc.
- Alcohols such as 75% alcohol, are the most commonly used disinfectants. However, its odor will be pungent and flammable, and its preparation, transportation and storage process have extremely high safety hazards. 4.
- Quaternary ammonium salts such as Jieermin and Xinjieermin, have strong bactericidal ability and can effectively kill bacteria, fungi and viruses.
- This type of disinfectant has a mild smell, is non-corrosive, can be completely dissolved in water, and can be directly used for skin and medical disinfection.
- Benzalkonium chloride a (N-alkyl-phenyl-dimethyl) ammonium chloride mixture, belongs to the cationic surfactants of the quaternary ammonium salts. Now it is mostly used in disinfectants or preservatives, and it is a broad-spectrum disinfectant. Because of its long-chain alkyl group, it can destroy the cell (wall) membrane of microorganisms and cause their death, thereby achieving the effect of sterilization. Viruses have no cell walls and are more fragile and easier to kill than bacteria. Therefore, the manufacturer has developed a variety of disinfectants containing benzalkonium chloride.
- Patent CN102065696B discloses a kind of universal sterilizing and disinfecting agent. .
- Patent CN201611024695 discloses a composite disinfectant composed of benzalkonium chloride and other surfactants. The disinfectant can efficiently kill 100% (log value>6) Escherichia coli, Staphylococcus aureus, white Streptococcus, Pseudomonas aeruginosa.
- Patent CN201010289039 discloses a composite antibacterial agent and its preparation method.
- Patent CN202010085304 discloses a formulation of a skin disinfectant cleaning solution and a preparation method thereof.
- the detergent is used in combination with benzalkonium chloride and cetyl chloramine, which can kill 100% (log value>5) large intestine within 1 minute. Bacillus, and kills 99.9% of the bacteria on the skin surface within 10 minutes.
- This method can be used for daily prevention of new coronaviruses, but no specific data has been disclosed.
- the present invention provides a novel disinfectant, comprising: an active agent, an auxiliary agent and a buffer; wherein the auxiliary agent comprises: a chelating agent, a reducing agent providing free sulfhydryl groups, a weak reducing agent and a reducing agent.
- the active agent is preferably a quaternary ammonium salt cationic surfactant, such as one or more of the following substances: benzalkonium chloride, benzalkonium bromide, benzethonium chloride, cetylpyridinium chloride.
- the preferred active agent is benzalkonium chloride.
- the chelating agent is preferably one or more of the following substances: ethylenediaminetetraacetic acid (EDTA), ethylenediaminetetraacetic acid sodium salt (EDTA- Na2 ), aminotriacetic acid (NTA), ethylene glycol diamine Ethyl ether diamine tetraacetic acid (EGTA), diethylene triamine pentaacetic acid (DTPA).
- EDTA ethylenediaminetetraacetic acid
- EDTA- Na2 ethylenediaminetetraacetic acid sodium salt
- NTA aminotriacetic acid
- EGTA ethylene glycol diamine Ethyl ether diamine tetraacetic acid
- DTPA diethylene triamine pentaacetic acid
- Particularly preferred chelating agents are ethylenediaminetetraacetic acid (EDTA) or ethylenediaminetetraacetic acid sodium salt (EDTA- Na2 ).
- the reducing agent providing free sulfhydryl is preferably one or more of the following substances: L-cysteine (L-Cysteine), reduced glutathione, ⁇ -mercaptoethanol. Particularly preferred is L-cysteine.
- the weak reducing agent is preferably one or more of the following substances: sodium sulfite (Na 2 SO 3 ), vitamin C, and vitamin E.
- a particularly preferred weak reducing agent is sodium sulfite.
- the reducing agent is preferably one or more of the following substances: dithiothreitol (DTT), tris(2-carboxyethyl)phosphine (TCEP).
- DTT dithiothreitol
- TCEP tris(2-carboxyethyl)phosphine
- a particularly preferred reducing agent is dithiothreitol.
- the adjuvant includes: EDTA or EDTA-Na 2 , L-cysteine, sodium sulfite, dithiothreitol.
- the buffer is preferably one or more of the following substances: Tris (Tris), 4-hydroxyethylpiperazine ethanesulfonic acid (HEPES), 3-morpholine propanesulfonic acid (MOPS) .
- Tris Tris
- HEPES 4-hydroxyethylpiperazine ethanesulfonic acid
- MOPS 3-morpholine propanesulfonic acid
- a particularly preferred buffer is Tris.
- the disinfectant comprises: benzalkonium chloride as active agent; EDTA- Na2 , L-cysteine, sodium sulfite, dithiothreitol as adjuvants; and as buffer dose of Tris.
- the concentration of benzalkonium chloride as the active agent ranges from 0.001% to 0.5% (W/V), preferably 0.01% (W/V).
- the concentrations of EDTA- Na2 , L-cysteine, sodium sulfite, dithiothreitol as adjuvants are each independently in the range of 0.01-100 mM; preferably, in the range of 1-10 mM.
- the disinfectant of the present invention is particularly suitable for disinfecting or inhibiting the new coronavirus.
- the disinfectant can be applied to the human body, such as hands, but also to public places (eg, hospitals, subways, schools, airports), logistics cold chains, or physical surfaces, such as containers.
- the invention provides a disinfectant with a low concentration of active agent as the main component, which has the characteristics of short action time, high bactericidal efficacy, mild conditions, no irritation, no pollution and the like. It can not only be used as a disinfectant for human surfaces (such as hands), but also very suitable for disinfection of public places where people gather, logistics cold chains, and large containers in ports.
- Coronavirus refers to a class of enveloped viruses that can cause disease in vertebrates, especially mammals or birds, having a single-stranded positive-stranded RNA genome. They belong to the order Nidovirales, the family Coronaviridae. Seven coronaviruses have been found to infect humans so far, including HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, SARS-CoV, MERS-CoV, and SARS-CoV-2. Some of the diseases they cause are mild, like the common flu, while others can be deadly, such as SARS, MERS, and COVID-19. The coronavirus that causes COVID-19 is SARS-CoV-2, also known as "coronavirus”.
- the present invention provides a novel disinfectant, comprising: an active agent, an auxiliary agent and a buffer; wherein the auxiliary agent comprises: a chelating agent, a reducing agent providing free sulfhydryl groups, a weak reducing agent and a reducing agent.
- the "active agent” can be a variety of conventional active agents suitable for bacterial and viral disinfecting.
- the preferred active agent is a quaternary ammonium salt cationic surfactant, for example, it can be one or more of the following substances: benzalkonium chloride, benzalkonium bromide, benzethonium chloride, cetylpyridinium chloride.
- a particularly preferred active agent is benzalkonium chloride.
- the active agents of the present invention may also include one or several other types of active agents, such as anionic surfactants or nonionic surfactants, and the like.
- Quaternary ammonium salt cationic surfactants have the advantages of low bactericidal concentration, non-irritant, non-toxic and non-corrosive, in addition to the surface adsorption of surfactants, the effect of reducing surface tension and a certain washing function.
- Buffers are used to provide a relatively stable solution environment.
- a near neutral pH eg, 5-8, is preferred.
- Various commonly used buffers such as Tris can be used.
- the adjuvant of the present invention plays an important role in enhancing the disinfecting effect of the disinfectant.
- Adjuvants include four types of components: chelating agents, reducing agents providing free sulfhydryl groups, weak reducing agents, and reducing agents.
- the chelating agent can chelate with heavy metal ions in water, reducing the influence of heavy metal ions on the effect of disinfectants.
- the chelating agent of the present invention may be EDTA or its sodium salt or the like.
- the reducing agent providing free sulfhydryl group is preferably one or more of the following substances, which play the role of stabilizing disinfectant: L-cysteine (L-Cysteine), reduced glutathione, beta mercaptoethanol. Particularly preferred is L-cysteine.
- the weak reducing agent is preferably one or more of the following substances, which play the role of stabilizing the disinfectant: sodium sulfite (Na 2 SO 3 ), vitamin C and its derivatives, vitamin E and its derivatives.
- a particularly preferred weak reducing agent is sodium sulfite.
- the reducing agent is preferably one or more of the following substances, which play the role of stabilizing the disinfectant: dithiothreitol (DTT), tris(2-carboxyethyl)phosphine (TCEP).
- DTT dithiothreitol
- TCEP tris(2-carboxyethyl)phosphine
- a particularly preferred reducing agent is dithiothreitol.
- Embodiment 1 the preparation of disinfectant
- Active agent benzalkonium chloride
- Tris buffer with a concentration of 10 mM, and then weigh each component raw material according to the disinfectant formula (see Example 3 for details), such as: benzalkonium chloride, L-Cysteine, DTT, Na 2 SO 3 , EDTA-Na 2 Add to Tris buffer and stir until completely dissolved. Finally, adjust the pH to 8.0-8.5 with HCl or NaOH, and make up to volume with pure water.
- the disinfectant formula see Example 3 for details
- Control reagent 10 mM Tris-HCl, pH 8.0.
- Neutralizer Dissolve 3g of Tween 80 in 100mL of water, weigh 0.3g of lecithin and add it to the solution. After fully dissolving, filter it with a 0.45 ⁇ m filter membrane and set it aside for use.
- the number of single colonies grown on the plate was used as the quantitative basis. Three plates were used for parallel testing in each group of sterilization experiments, and the average number of single colonies on the three plates was taken.
- Embodiment 3 disinfectant sterilization effect evaluation
- the sterilization potency evaluation was carried out on the various components in the disinfectant and the formulations formed by different combinations of the various components.
- Disinfectant buffer + active agent + auxiliary
- Buffer 10mM Tris-HCl, pH 8.0,
- Active agent benzalkonium chloride (W/V) 0.1%
- the active agent benzalkonium chloride
- the active agent has strong bactericidal activity when used alone, but cannot achieve 100% bactericidal effect within 10 seconds.
- 100% bactericidal effect can be achieved within 10 seconds. It can be seen that the auxiliary agent and the buffer can improve the disinfecting efficiency of the active agent, and the buffer alone has no disinfecting effect.
- auxiliaries and buffers can reduce the use concentration of active agents.
- auxiliary (1 mM EDTA-Na 2 , 10 mM L-Cysteine, 5 mM Na 2 SO 3 , 10 mM DTT) and buffer (10 mM Tris-HCl, pH 8.0) as fixed components different concentrations of benzalkonium chloride were tested on the Killing rate of the tested bacteria.
- the active agent with a concentration of 0.01% can kill all the tested bacteria within 10 seconds.
- the concentration of active agent used is 1/10 of the common concentration (0.1%) of similar products, and the killing time is 1/6 of the common time (1 minute) of similar products.
- test sample formula is as follows:
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Environmental Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pest Control & Pesticides (AREA)
- Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Dentistry (AREA)
- Microbiology (AREA)
- Agronomy & Crop Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
提供了一种新型消毒液，包含：活性剂、助剂和缓冲剂；其中所述助剂包含：螯合剂、提供自由巯基的还原剂、弱还原剂和还原剂。所述消毒剂特别适用于新冠病毒的消杀。
Description
本发明涉及消毒剂领域。
新型冠状病毒肺炎(简称“新冠肺炎”或“Covid-19”)是一种急性感染性肺炎，目前尚无特效药。目前，该病毒已在全球广泛传播，导致数千万人感染。
Covid-19疫情以来，社会对消毒剂的需求与日俱增。目前市场上的消毒剂主要分为四类。1、酚类，如滴露，该类消毒剂杀菌效果良好，但其气味刺激，微溶于水且有残留性和腐蚀性。2、次氯酸类，如84消毒液，虽然其具有良好杀菌效果，但具有很强的刺激性和腐蚀性，常用于液体消毒，如游泳池、自来水等。3、醇类，如75％酒精，是目前最常用的消毒剂。但是其气味会比较刺鼻并且具有易燃性，其制备、运输、储存过程中都有极高安全隐患。4、季铵盐类，如洁尔灭，新洁尔灭，该类杀菌能力强，能够有效杀灭细菌、真菌和病毒。该类消毒剂气味温和，无腐蚀性，可以完全溶于水，可以直接用于皮肤和医用消毒。
苯扎氯铵，一种氯化(N-烷基-苯基-二甲基)铵混合物，属于季铵盐类的阳离子表面活性剂。现多用于消毒剂或防腐剂中，是一种广谱性消毒剂。由于其具有长链烷基基团，能破坏微生物的细胞(壁)膜，致其死亡，从而达到杀菌的效果。病毒没有细胞壁，比细菌更脆弱，更容易杀灭。因此生产商开发出多种含苯扎氯铵的消毒剂，专利CN102065696B公开了一种万能杀菌消毒剂，该消毒剂以苯扎氯铵、山梨酸、苯甲酸等作为活性剂，具有高效杀菌能力。但是其活性pH 2.5-4.0，呈酸性，显然不适合推广使用。专利CN201611024695公开了一种以苯扎氯铵和其它表面活性剂组成的复合消毒剂，该消毒剂能高效在5分钟内100％杀灭(对数值>6)大肠杆菌、金黄色葡萄球菌、白色链球菌、铜绿假单胞菌。专利CN201010289039公开了一种复合抗菌剂及其制备方法。该方法以苯扎氯铵、二癸基二甲基氯化铵和ε-多聚赖氨酸作为主要抑菌成分，能在2分钟内100％杀灭(对数值>4)大肠杆菌、金黄色葡萄球菌、白色链球菌。专利CN202010085304公开了一种皮肤消毒清洁液的配方及其制备方法，该洗涤剂以苯扎氯铵和西吡氯胺复配使用，能在1分钟内100％杀灭(对数值>5)大肠杆菌，并且在10分钟内杀灭99.9％皮肤表面细菌，该专利提到此方法能用于日常预防新型冠状病毒，但尚无具体数据披露。
以上消毒液虽具有高效杀灭微生物的性能，但消杀所需时间仍较长，难以满足多种应用场景下对快速消杀的需求，且成分复杂，制备工艺繁琐，生产成本较高，使用后对环境造成一定污染。目前，Covid-19普遍存在“物传人”和“环境传人”现象，亟需一种适用于人、物体表面的瞬时、高效消毒剂有效切断病毒传播链条。
发明概述
本发明提供了一种新型消毒剂，包含：活性剂、助剂和缓冲剂；其中所述助剂包含：螯合剂、提供自由巯基的还原剂、弱还原剂和还原剂。
所述活性剂优选为季铵盐类阳离子表面活性剂，例如可以是下列物质中的一种或几种：苯扎氯铵、苯扎溴铵、苄索氯铵、西吡氯铵。优选的活性剂为苯扎氯铵。
所述螯合剂优选为下列物质中的一种或几种：乙二胺四乙酸(EDTA)、乙二胺四乙酸钠盐(EDTA-Na
2)、氨基三乙酸(NTA)、乙二醇二乙醚二胺四乙酸(EGTA)、二亚乙基三胺五乙酸(DTPA)。特别优选的螯合剂为乙二胺四乙酸(EDTA)或乙二胺四乙酸钠盐(EDTA-Na
2)。
所述提供自由巯基的还原剂优选为下列物质中的一种或几种：L-半胱氨酸(L-Cysteine)、还原型谷胱甘肽、β巯基乙醇。特别优选的是L-半胱氨酸。
所述弱还原剂优选为下列物质中的一种或几种：亚硫酸钠(Na
2SO
3)、维生素C、维生素E。特别优选的弱还原剂是亚硫酸钠。
所述还原剂优选为下列物质中的一种或几种：二硫苏糖醇(DTT)、三(2-羧乙基)膦(TCEP)。特别优选的还原剂为二硫苏糖醇。
在优选实施方案中，所述助剂包括：EDTA或EDTA-Na
2、L-半胱氨酸、亚硫酸钠、二硫苏糖醇。
所述缓冲剂优选为下列物质中的一种或几种：三羟甲基氨基甲烷(Tris)、4-羟乙基哌嗪乙磺酸(HEPES)、3-吗啉丙磺酸(MOPS)。特别优选的缓冲剂为Tris。
在特别优选的实施方案中，所述消毒剂包含：作为活性剂的苯扎氯铵；作为助剂的EDTA-Na
2、L-半胱氨酸、亚硫酸钠、二硫苏糖醇；以及作为缓冲剂的Tris。
在一些实施方案中，作为活性剂的苯扎氯铵浓度为0.001％-0.5％(W/V)，优选为0.01％(W/V)。
在一些实施方案中，作为助剂的EDTA-Na
2、L-半胱氨酸、亚硫酸钠、二硫苏糖醇浓度各自独立地在0.01-100mM范围内；优选地，在1-10mM范围内。
本发明的消毒剂特别适用于消杀或抑制新冠病毒。所述消毒剂可以施用于人体，例如手部，也可以施用于公共场所(例如医院、地铁、学校、机场)、物流冷链或物理表面，例如集装箱。
本发明提供了一种以低浓度活性剂为主要组分的消毒剂，具有作用时间短、杀菌效力高、条件温和、无刺激性、无污染等特点。既可以作为人体表面(如手部)消毒液，也非常适用于人员聚集的公共场所、物流冷链、港口大型集装箱等表面的消毒。
除非另有说明，本文使用的所有技术和科学术语具有本领域普通技术人员所通常理解的含义。
“冠状病毒(coronavirus)”指可在脊椎动物、尤其是哺乳动物或鸟类中引起疾病的一类包膜病毒，具有单股正链RNA基因组。它们在系统分类上属套式病毒目(Nidovirales)，冠状病毒科(Coronaviridae)。迄今已发现7种冠状病毒可感染人类，包括HCoV-229E、HCoV-OC43、HCoV-NL63、HCoV-HKU1、SARS-CoV、MERS-CoV、和SARS-CoV-2。它们引起的疾病中，有些症状比较温和，类似普通流感，而另一些则可能是致命的，例如SARS、MERS和COVID-19。引起COVID-19的冠状病毒为SARS-CoV-2，也称为“新冠病毒”。
本发明提供了一种新型消毒剂，包含：活性剂、助剂和缓冲剂；其中所述助剂包含：螯合剂、提供自由巯基的还原剂、弱还原剂和还原剂。
“活性剂”可以是适用于细菌和病毒消杀的各种常用活性剂。优选的活性剂为季铵盐类阳离子表面活性剂，例如可以是下列物质中的一种或几种：苯扎氯铵、苯扎溴铵、苄索氯铵、西吡氯铵。特别优选的活性剂为苯扎氯铵。
本发明的活性剂也可以包括一种或几种其他类型的活性剂，例如阴离子表面活性剂或非离子表面活性剂等。
季铵盐类阳离子表面活性剂具有杀菌浓度低、无刺激性、无毒、无腐蚀性的优点，此外还有表面活性剂的表面吸附、降低表面张力的作用并具有一定的洗涤功能。
缓冲剂用于提供相对稳定的溶液环境。优选为接近中性的pH，例如5-8。可以使用各种常用的缓冲剂，例如Tris。
本发明的助剂对于增强消毒剂的消杀效力具有重要作用。助剂包括四类组分：螯合剂、提供自由巯基的还原剂、弱还原剂和还原剂。
螯合剂可以与水中重金属离子鳌合，降低重金属离子对消毒剂效果的影响。本发明的螯合剂可以是EDTA或其钠盐等。
提供自由巯基的还原剂优选为下列物质中的一种或几种，起到稳定消毒剂的作用：L-半胱氨酸(L-Cysteine)、还原型谷胱甘肽、β巯基乙醇。特别优选的是L-半胱氨酸。
弱还原剂优选为下列物质中的一种或几种，起到稳定消毒剂的作用：亚硫酸钠(Na
2SO
3)、维生素C及其衍生物、维生素E及其衍生物。特别优选的弱还原剂是亚硫酸钠。
还原剂优选为下列物质中的一种或几种，起到稳定消毒剂的作用：二硫苏糖醇(DTT)、三(2-羧乙基)膦(TCEP)。特别优选的还原剂为二硫苏糖醇。
除非另有说明，否则本说明书中所使用的方法及技术一般根据本领域公知的和常规的方法和本说明书中所阐述的或引用的各种参考文献中所述的方式来进行。
实施例1、消毒剂的配制
1)消毒剂组分：
缓冲剂：Tris，
活性剂：苯扎氯铵，
助剂：EDTA-Na
2、L-Cysteine、Na
2SO
3、DTT。
2)消毒剂配制：
配制浓度为10mM的Tris缓冲液，再根据消毒剂配方(详见实施例3)称取各组分原料，如：苯扎氯铵、L-Cysteine、DTT、Na
2SO
3、EDTA-Na
2加入Tris缓冲液中，搅拌至完全溶解。最后用HCl或者NaOH调pH至8.0-8.5，纯水定容。
3)其他试剂配制
对照试剂：10mM Tris-HCl，pH 8.0。
中和剂：取3g Tween 80溶解于100mL水中，称取0.3g卵磷脂加入溶液中，充分溶解后用0.45μm滤膜过滤，待用。
实施例2、消杀效果评价
1)菌液制备：将金黄色葡萄球菌(ATCC 6538)、大肠杆菌(CICC 10899)接种于LB固体平板，于37℃培养。待生长出单菌落后，挑取单菌落至液体LB培养基，于37℃培养。当菌液OD600达到0.6-0.8(菌对数值>8)时，离心收集菌体，弃上清，用等体积的缓冲液重悬菌体，置于冰上，待用。
2)杀菌实验：取10μL菌液至1.5mL EP管中，然后再向EP管中加入90μL消毒剂，混匀，室温反应10秒，立即加入900μL中和剂。然后将EP管中的反应产物全部涂布到LB固体平板中，置于37℃培养24-28小时。
另外取10μL菌液至1.5mL EP管中，然后再向EP管中加入90μL缓冲液，混匀，室温反应10秒，立即加入900μL中和剂。然后将EP管中的反应产物逐级稀释至10
-10倍后，涂布到LB固体平板中，置于37℃培养24-28小时，作为对照。
以平板上生长出的单菌落数作为定量依据，每组消杀实验采用三个平板平行测试，取三个平板的单菌落数平均值。
实施例3、消毒剂杀菌效果评价
根据实施例2所述的方法，对消毒剂中各类组分及各类组分以不同组合方式形成的配方进行杀菌效价评价。
1)消毒剂和消毒剂中各类组分的消杀效果评价：
消毒剂：缓冲剂+活性剂+助剂，
缓冲剂：10mM Tris-HCl，pH 8.0，
活性剂：苯扎氯铵(W/V)0.1％，
助剂：1mM EDTA-Na
2+10mM L-Cysteine+5mM Na
2SO
3+10mM DTT分别使用以上三类组分及三类组分的混合液(消毒剂)，按照实施例2所述的方法进行杀菌实验，结果如下：
活性剂苯扎氯铵单独使用即具有较强的杀菌活性，但无法在10秒钟内达到100％的杀菌效果。当苯扎氯铵配合缓冲剂和助剂同时使用，则可在10秒钟达到100％的杀菌效果。可见，助剂和缓冲剂能提高活性剂的消杀效率，缓冲剂单独使用无消杀效果。
2)助剂和缓冲剂的添加可降低活性剂的使用浓度。以助剂(1mM EDTA-Na
2、10mM L-Cysteine、5mM Na
2SO
3、10mM DTT)和缓冲剂(10mM Tris-HCl，pH 8.0)作为固定组分，测试不同浓度的苯扎氯铵对受试菌的杀灭率。
如下表所示：
结果表明，在配合使用助剂和缓冲剂的情况下，浓度为0.01％的活性剂即可在10秒内杀灭所有受试菌。活性剂使用浓度是同类产品常用浓度(0.1％)的1/10，杀灭时间是同类产品常用时间(1分钟)的1/6。
2)0.01％的活性剂苯扎氯铵与不同助剂配方配合使用的消杀效果：
测试样品配方如下表：
按照实施例2方法验证杀菌效果，结果如下：
结果表明，本发明中消毒剂的助剂中各组分相互独立，互不影响，且仅当同时配合使用所有助剂组分，才能达到100％的杀灭效率。
Claims (25)
- 一种消毒剂，包含：活性剂、助剂和缓冲剂；其中所述助剂包含：螯合剂、提供自由巯基的还原剂、弱还原剂和还原剂。
- 如权利要求1所述的消毒剂，其中所述活性剂为季铵盐类阳离子表面活性剂。
- 如权利要求1所述的消毒剂，其中所述活性剂包括下列物质中的一种或几种：苯扎氯铵、苯扎溴铵、苄索氯铵、西吡氯铵。
- 如权利要求1所述的消毒剂，其中所述活性剂为苯扎氯铵。
- 如权利要求1-4任一项所述的消毒剂，其中所述螯合剂包括下列物质中的一种或几种：乙二胺四乙酸(EDTA)、乙二胺四乙酸钠盐(EDTA-Na 2)、氨基三乙酸(NTA)、乙二醇二乙醚二胺四乙酸(EGTA)、二亚乙基三胺五乙酸(DTPA)。
- 如权利要求1-5任一项所述的消毒剂，其中所述螯合剂为乙二胺四乙酸(EDTA)或乙二胺四乙酸钠盐(EDTA-Na 2)。
- 如权利要求1-6任一项所述的消毒剂，其中所述提供自由巯基的还原剂包括下列物质中的一种或几种：L-半胱氨酸(L-Cysteine)、还原型谷胱甘肽、β巯基乙醇。
- 如权利要求1-7任一项所述的消毒剂，其中所述提供自由巯基的还原剂为L-半胱氨酸。
- 如权利要求1-8任一项所述的消毒剂，其中所述弱还原剂包括下列物质中的一种或几种：亚硫酸钠(Na 2SO 3)、维生素C、维生素E。
- 如权利要求1-9任一项所述的消毒剂，其中所述弱还原剂为亚硫酸钠。
- 如权利要求1-10任一项所述的消毒剂，其中所述还原剂包括下列物质中的一种或几种：二硫苏糖醇(DTT)、三(2-羧乙基)膦(TCEP)。
- 如权利要求1-11任一项所述的消毒剂，其中所述还原剂为二硫苏糖醇。
- 如权利要求1-12任一项所述的消毒剂，其中所述助剂包括：EDTA或EDTA-Na 2、L-半胱氨酸、亚硫酸钠、二硫苏糖醇。
- 如权利要求1-13任一项所述的消毒剂，其中所述缓冲剂包括下列物质中的一种或几种：三羟甲基氨基甲烷(Tris)、4-羟乙基哌嗪乙磺酸(HEPES)、3-吗啉丙磺酸(MOPS)。
- 如权利要求1-14任一项所述的消毒剂，其中所述缓冲剂为Tris。
- 如权利要求1-15任一项所述的消毒剂，其中所述消毒剂包含：作为活性剂的苯扎氯铵；作为助剂的EDTA-Na 2、L-半胱氨酸、亚硫酸钠、二硫苏糖醇；以及作为缓冲剂的Tris。
- 如权利要求1-16任一项所述的消毒剂，其中作为活性剂的苯扎氯铵浓度为0.001％-0.5％(W/V)。
- 如权利要求1-16任一项所述的消毒剂，其中作为活性剂的苯扎氯铵浓度为0.01％(W/V)。
- 如权利要求1-18任一项所述的消毒剂，其中作为助剂的EDTA-Na 2、L-半胱氨酸、亚硫酸钠、二硫苏糖醇浓度各自独立地在0.01-100mM范围内。
- 如权利要求1-19任一项所述的消毒剂，其中作为助剂的EDTA-Na 2、L-半胱氨酸、亚硫酸钠、二硫苏糖醇浓度各自独立地在1-10mM范围内。
- 如权利要求1-20任一项所述的消毒剂用于消杀或抑制新冠病毒的应用。
- 如权利要求21所述的应用，其中所述消毒剂施用于人体表面。
- 如权利要求21所述的应用，其中所述消毒剂施用于物体表面。
- 如权利要求1-20任一项所述的消毒剂用于消杀或抑制细菌的应用。
- 如权利要求24所述的应用，其中所述细菌为大肠杆菌或金黄色葡萄球菌。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202280014070.5A CN117082978A (zh) | 2021-02-10 | 2022-02-10 | 消毒剂 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110185531 | 2021-02-10 | ||
| CN202110185531.2 | 2021-02-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2022171153A1 true WO2022171153A1 (zh) | 2022-08-18 |
Family
ID=82837465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2022/075750 WO2022171153A1 (zh) | 2021-02-10 | 2022-02-10 | 消毒剂 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN117082978A (zh) |
| WO (1) | WO2022171153A1 (zh) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06279268A (ja) * | 1993-01-27 | 1994-10-04 | Takeda Chem Ind Ltd | 消毒殺菌剤およびこれを含有するエアゾール組成物 |
| CN104621104A (zh) * | 2015-02-02 | 2015-05-20 | 山东威高药业股份有限公司 | 一种低腐蚀性消毒剂 |
| CN109316536A (zh) * | 2018-10-22 | 2019-02-12 | 湖南中威制药有限公司 | 一种皮肤黏膜消毒剂及其制备方法 |
| CN112043701A (zh) * | 2020-09-24 | 2020-12-08 | 上海中医药大学 | 长链季铵盐类化合物的医药用途 |
| CN112042645A (zh) * | 2020-08-22 | 2020-12-08 | 西北工业大学 | 一种复合季铵盐消毒剂 |
-
2022
- 2022-02-10 WO PCT/CN2022/075750 patent/WO2022171153A1/zh active Application Filing
- 2022-02-10 CN CN202280014070.5A patent/CN117082978A/zh active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06279268A (ja) * | 1993-01-27 | 1994-10-04 | Takeda Chem Ind Ltd | 消毒殺菌剤およびこれを含有するエアゾール組成物 |
| CN104621104A (zh) * | 2015-02-02 | 2015-05-20 | 山东威高药业股份有限公司 | 一种低腐蚀性消毒剂 |
| CN109316536A (zh) * | 2018-10-22 | 2019-02-12 | 湖南中威制药有限公司 | 一种皮肤黏膜消毒剂及其制备方法 |
| CN112042645A (zh) * | 2020-08-22 | 2020-12-08 | 西北工业大学 | 一种复合季铵盐消毒剂 |
| CN112043701A (zh) * | 2020-09-24 | 2020-12-08 | 上海中医药大学 | 长链季铵盐类化合物的医药用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117082978A (zh) | 2023-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2503627C (en) | Hydrogen peroxide disinfectant containing a cyclic carboxylic acid and/or aromatic alcohol | |
| US8940792B2 (en) | Antimicrobial composition and methods for using same | |
| CN107624785A (zh) | 一种低腐蚀性单过硫酸氢钾复合盐消毒剂 | |
| US20100261631A1 (en) | Biofilm-removing agent | |
| CN104719336A (zh) | 一种低腐蚀性单过硫酸氢钾复合盐消毒剂 | |
| CN108605933B (zh) | 一种脂肪酸复合物 | |
| CN113287627B (zh) | 一种含过硫酸氢钾复合物的清洁消毒剂及使用方法、应用 | |
| CN101032254A (zh) | 一种稳定的过氧化氢空气消毒液 | |
| CN109077054A (zh) | 一种过氧乙酸复合消毒剂及其制备方法 | |
| CN112022732A (zh) | 一种免洗手消毒液及其制备方法 | |
| EP0375149A2 (en) | Virucidal low toxicity compositions | |
| CN108477209A (zh) | 一种消毒液及其制备方法 | |
| JPS6322503A (ja) | 液体殺菌剤 | |
| Maillard | Factors affecting the activities of microbicides | |
| WO2022171153A1 (zh) | 消毒剂 | |
| US20070286907A1 (en) | Germicide composition | |
| US6462088B1 (en) | Disinfecting preparation containing chlorine in alcohol | |
| CA2062006C (en) | Disinfectant with wide spectrum germicidal activity | |
| WO2022126976A1 (zh) | 一种肉类食品专用消毒液及其制备方法 | |
| JP4773518B2 (ja) | 結核菌殺菌活性が増大し臭気が減少した、酢酸塩およびアルコールを用いたグルタルアルデヒド消毒薬 | |
| CN117581869A (zh) | 消毒剂 | |
| CN110463721A (zh) | 一种基于过氧化氢的消毒灭菌剂及其制备方法 | |
| GB2292888A (en) | Wide spectrum water soluble biocide for medical instruments based on potassium monoperoxysulphate, malic & sulphamic acids, EDTA sodium salt & a glycol ether | |
| CN115474609B (zh) | 消毒液及其制备方法和膜层 | |
| SU1706634A1 (ru) | Дезинфицирующее средство |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22752313 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 202280014070.5 Country of ref document: CN |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 22752313 Country of ref document: EP Kind code of ref document: A1 |